肿瘤细胞治疗研究
英文原题：CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.
CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.
工程化T细胞已改变了血液肿瘤学，但携带CAR转基因的T细胞恶性肿瘤已成为CAR-T治疗后一种罕见且严重的基因组安全性信号。
工程化T细胞已改变了血液肿瘤学，但携带CAR转基因的T细胞恶性肿瘤已成为CAR-T治疗后一种罕见且严重的基因组安全性信号。现有数据支持多步骤模型，其中预先存在的克隆适应性、CAR-T制备、载体整合、构建体生物学和输注后选择可能在不同程度上发挥作用。我们综述了已报道的CAR转基因T细胞淋巴增殖性肿瘤（CTTLN）病例，并提出了实用的诊断标准以及与之相称的基因组监测方法。
Engineered T-cells have transformed hematooncology, but CAR transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR-T therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR-T manufacture, vector integration, construct biology and post-infusion selection may contribute to different degrees. We review reported cases of CAR-transgenic T-cell lymphoproliferative neoplasms (CTTLN) and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
MEMBER ACCOUNT
登录成功会直接打开下一页。
